The fungicide fludioxonil antagonizes fluconazole activity in the human fungal pathogen Candida albicans.
Name:
Buschart-Bilitewski_final.pdf
Size:
623.8Kb
Format:
PDF
Description:
original manuscript
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2012-12
Metadata
Show full item recordAbstract
The fungicide fludioxonil is widely used in agriculture. Residua of this fungicide are occasionally detected in fruits and can therefore be ingested by humans. The human fungal pathogen Candida albicans expresses the target of fludioxonil, Nik1p, a type III histidine kinase involved in stress response. Inhibition of yeast and hyphae growth was hardly observable after treatment of C. albicans SC5314 with fludioxonil. As a side effect, however, we observed a concentration-dependent induction of the expression of the genes CDR1 and CDR2, encoding ATP-binding cassette (ABC) transporters. This was independent of the presence of the target of fludioxonil as induction was also observed in a Δnik1 deletion mutant. Deletion of the CDR1 gene aggravated the inhibition of germ tube formation by fludioxonil, indicating that, in the wild-type, the fungicide was discharged from the cell by Cdr1p. Cdr1p is also known as a resistance factor of C. albicans against the commonly used antimycotic fluconazole. Thus, the effect of concurrent exposure to fludioxonil and known cargoes of ABC transporters on their extrusion and the growth of C. albicans was examined. Pre-incubation with fludioxonil decreased the export rate of rhodamine 6G. The resistance to fluconazole was increased by fludioxonil, independently of Nik1p. Therefore, exposure of C. albicans to fludioxonil may lead to increased resistance to fluconazole treatment.Citation
The fungicide fludioxonil antagonizes fluconazole activity in the human fungal pathogen Candida albicans. 2012, 61 (Pt 12):1696-703 J. Med. Microbiol.Affiliation
Biological Systems Analysis, Helmholtz Centre for Infection Research, Braunschweig, Germany.Journal
Journal of medical microbiologyPubMed ID
22918865Type
ArticleLanguage
enISSN
1473-5644ae974a485f413a2113503eed53cd6c53
10.1099/jmm.0.050963-0
Scopus Count
The following license files are associated with this item:
Related articles
- ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates.
- Authors: Holmes AR, Lin YH, Niimi K, Lamping E, Keniya M, Niimi M, Tanabe K, Monk BC, Cannon RD
- Issue date: 2008 Nov
- Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance.
- Authors: Niimi M, Niimi K, Takano Y, Holmes AR, Fischer FJ, Uehara Y, Cannon RD
- Issue date: 2004 Dec
- Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients.
- Authors: Maebashi K, Niimi M, Kudoh M, Fischer FJ, Makimura K, Niimi K, Piper RJ, Uchida K, Arisawa M, Cannon RD, Yamaguchi H
- Issue date: 2001 May
- Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents.
- Authors: Henry KW, Cruz MC, Katiyar SK, Edlind TD
- Issue date: 1999 Aug
- Expression of Major Efflux Pumps in Fluconazole-Resistant Candida albicans.
- Authors: Pourakbari B, Teymuri M, Mahmoudi S, Valian SK, Movahedi Z, Eshaghi H, Mamishi S
- Issue date: 2017